On Tuesday, Cytokinetics Inc (NASDAQ: CYTK) was 4.26% up from the session before settling in for the closing price of $33.13. A 52-week range for CYTK has been $29.31 – $61.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -7.22%. When this article was written, the company’s average yearly earnings per share was at -8.95%. With a float of $116.76 million, this company’s outstanding shares have now reached $119.22 million.
Considering the fact that the conglomerate employs 498 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -1359.51%, operating margin of -2943.3%, and the pretax margin is -3201.47%.
Cytokinetics Inc (CYTK) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytokinetics Inc stocks. The insider ownership of Cytokinetics Inc is 2.23%, while institutional ownership is 116.08%. The most recent insider transaction that took place on Jun 05 ’25, was worth 117,843. Before that another transaction happened on Jun 05 ’25, when Company’s Director sold 3,636 for $32.10, making the entire transaction worth $116,716. This insider now owns 29,658 shares in total.
Cytokinetics Inc (CYTK) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -8.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.60% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
You can see what Cytokinetics Inc (CYTK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 214.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.31, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -5.06 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Compared to the last year’s volume of 1.88 million, its volume of 1.29 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 92.25%. Additionally, its Average True Range was 1.53.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 22.26%, which indicates a significant decrease from 98.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.23% in the past 14 days, which was lower than the 60.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.31, while its 200-day Moving Average is $46.45.
